國立虎尾科技大學 |

New Rapid-acting Antidepressants

Record Type:	Language materials, printed : Monograph/item
Title/Author:	New Rapid-acting Antidepressants/ edited by Kenji Hashimoto, Mario Manto.
other author:	Hashimoto, Kenji.
Description:	VII, 149 p. 14 illus., 9 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Neurosciences. -
Online resource:	https://doi.org/10.1007/978-3-030-79790-4
ISBN:	9783030797904

New Rapid-acting Antidepressants
New Rapid-acting Antidepressants[electronic resource] /edited by Kenji Hashimoto, Mario Manto. - 1st ed. 2021. - VII, 149 p. 14 illus., 9 illus. in color.online resource. - Contemporary Clinical Neuroscience,2627-5341. - Contemporary Clinical Neuroscience,.

(R)-ketamine: A new rapid-acting antidepressant -- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms -- Predictable biomarkers for rapid-acting antidepressant response to ketamine -- Nitrous Oxide: an old compound with emerging psychotropic properties -- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants -- AMPA receptor potentiators as potential rapid-acting antidepressants -- mGlu2/3 receptor antagonists as rapid-acting antidepressants -- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.

This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists, psychiatrists, and those who want to learn about CNS drugs at the graduate level.

ISBN: 9783030797904

Standard No.: 10.1007/978-3-030-79790-4doiSubjects--Topical Terms:

593561
Neurosciences.

LC Class. No.: RC321-580

Dewey Class. No.: 612.8

New Rapid-acting Antidepressants
LDR:02980nam a22004095i 4500 001 1056529
003 DE-He213
005 20211022124140.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030797904 $9 978-3-030-79790-4
024 7 $a 10.1007/978-3-030-79790-4 $2 doi
035 $a 978-3-030-79790-4
050 4 $a RC321-580
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 612.8 $2 23
245 1 0 $a New Rapid-acting Antidepressants $h [electronic resource] / $c edited by Kenji Hashimoto, Mario Manto.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a VII, 149 p. 14 illus., 9 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Contemporary Clinical Neuroscience, $x 2627-5341
505 0 $a (R)-ketamine: A new rapid-acting antidepressant -- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms -- Predictable biomarkers for rapid-acting antidepressant response to ketamine -- Nitrous Oxide: an old compound with emerging psychotropic properties -- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants -- AMPA receptor potentiators as potential rapid-acting antidepressants -- mGlu2/3 receptor antagonists as rapid-acting antidepressants -- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.
520 $a This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists, psychiatrists, and those who want to learn about CNS drugs at the graduate level.
650 0 $a Neurosciences. $3 593561
700 1 $a Hashimoto, Kenji. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1251028
700 1 $a Manto, Mario. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1071175
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030797898
776 0 8 $i Printed edition: $z 9783030797911
776 0 8 $i Printed edition: $z 9783030797928
830 0 $a Contemporary Clinical Neuroscience, $x 2627-535X $3 1254587
856 4 0 $u https://doi.org/10.1007/978-3-030-79790-4
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)